Inhibitors of angiogenesis enter phase III testing.
N J
NJ
Nelson
D043168:Angiostatins; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D017326:Clinical Trials, Phase III as Topic; D003094:Collagen / Q000627:therapeutic use; D043169:Endostatins; D004730:Endothelium, Vascular / Q000187:drug effects*; D006801:Humans; D006877:Hydroxamic Acids / Q000627:therapeutic use; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009930:Organic Chemicals; D010446:Peptide Fragments / Q000627:therapeutic use; D010654:Phenylbutyrates; D010958:Plasminogen / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D043169:Endostatins; D006877:Hydroxamic Acids; D009930:Organic Chemicals; D010446:Peptide Fragments; D010654:Phenylbutyrates; C113282:prinomastat; D043168:Angiostatins; D010958:Plasminogen; D003094:Collagen; C113281:Bay 12-9566; C100342:marimastat; D008666:Metalloendopeptidases